Literature DB >> 18777572

Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids.

Lumír Ondrej Hanus1.   

Abstract

Research on the chemistry and pharmacology of cannabinoids and endocannabinoids has reached enormous proportions, with approximately 15,000 articles on Cannabis sativa L. and cannabinoids and over 2,000 articles on endocannabinoids. The present review deals with the history of the Cannabis sativa L. plant, its uses, constituent compounds and their biogeneses, and similarity to compounds from Radula spp. In addition, details of the pharmacology of natural cannabinoids, as well as synthetic agonists and antagonists are presented. Finally, details regarding the pioneering isolation of the endocannabinoid anandamide, as well as the pharmacology and potential therapeutic uses of endocannabinoid congeners are presented. (c) 2008 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18777572     DOI: 10.1002/med.20135

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  21 in total

Review 1.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

Review 2.  "Herbal incense": designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays.

Authors:  Torbjörn U C Järbe; Roger S Gifford
Journal:  Life Sci       Date:  2013-07-25       Impact factor: 5.037

Review 3.  Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.

Authors:  John M McPartland; Marnie Duncan; Vincenzo Di Marzo; Roger G Pertwee
Journal:  Br J Pharmacol       Date:  2015-02       Impact factor: 8.739

Review 4.  Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation?

Authors:  Jürg Gertsch
Journal:  Br J Pharmacol       Date:  2017-01-16       Impact factor: 8.739

5.  Is Cannabis of Potential Value as a Therapeutic for Inflammatory Bowel Disease?

Authors:  Timna Naftali
Journal:  Dig Dis Sci       Date:  2019-10       Impact factor: 3.199

6.  Estrogen-related receptor γ controls hepatic CB1 receptor-mediated CYP2E1 expression and oxidative liver injury by alcohol.

Authors:  Don-Kyu Kim; Yong-Hoon Kim; Hyun-Hee Jang; Jinyoung Park; Jung Ran Kim; Minseob Koh; Won-Il Jeong; Seung-Hoi Koo; Tae-Sik Park; Chul-Ho Yun; Seung Bum Park; John Y L Chiang; Chul-Ho Lee; Hueng-Sik Choi
Journal:  Gut       Date:  2012-09-29       Impact factor: 23.059

7.  Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.

Authors:  Torbjörn U C Järbe; Brian J LeMay; V Kiran Vemuri; Subramanian K Vadivel; Alexander Zvonok; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2011-03-03       Impact factor: 4.530

8.  A high efficacy cannabinergic ligand (AM4054) used as a discriminative stimulus: Generalization to other adamantyl analogs and Δ(9)-THC in rats.

Authors:  Torbjörn U C Järbe; Brian J LeMay; Ganesh A Thakur; Alexandros Makriyannis
Journal:  Pharmacol Biochem Behav       Date:  2016-06-02       Impact factor: 3.533

Review 9.  Modulating the endocannabinoid system in human health and disease--successes and failures.

Authors:  Pál Pacher; George Kunos
Journal:  FEBS J       Date:  2013-04-22       Impact factor: 5.542

10.  Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors.

Authors:  Mark Bauer; Andrea Chicca; Marco Tamborrini; David Eisen; Raissa Lerner; Beat Lutz; Oliver Poetz; Gerd Pluschke; Jürg Gertsch
Journal:  J Biol Chem       Date:  2012-09-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.